AI Article Synopsis
- The study aimed to analyze how ginkgolide B is processed in rats after injection.
- Serum levels of ginkgolide B were measured using LC-MS, and pharmacokinetic parameters were calculated with DAS2.0 software.
- Results showed consistent peak times with varying maximum concentrations and overall exposure, suggesting ginkgolide B follows a three-compartment model in rats.
Article Abstract
Objective: To study the pharmacokinetics of ginkgolide B for injection in rats.
Methods: The serum concentration of ginkgolide B was determined by LC-MS and calculate its parameter of pharmacokinetics via DAS2.0 software.
Results: After intravenous of 0.75, 3.75 and 14.0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0.083 +/- 0) h, Cmax were (422.312 +/- 14.203), (1608.467 +/- 226.677), (1987.036 +/- 237.202) microg/L, AUC0-1 were (533.833 +/- 114.943), (1786.029 +/- 137.066), (1943.44 +/- 415.892) microg x h/L.
Conclusion: Ginkgolide B has three compartment model in rats.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic Study of Ginkgolide B in Dog After Intravenous Administration.
Biomed Chromatogr
February 2025
Department of Pharmacy, Xuzhou Central Hospital, Xuzhou, China.
Article Synopsis
- Ginkgolide B (GB), found in Ginkgo biloba, shows promise in treating cognitive declines, but its pharmacokinetics were poorly understood.
- A new LC-MS/MS method allowed for precise measurement of GB in dog plasma, using a liquid-liquid extraction technique.
- The study revealed that GB's pharmacokinetics in dogs are dose-proportional, providing valuable insights for future clinical applications.
[Not Available].
Acta Pharm Sin B
January 2024
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou 510632, China.
Bioactive compounds derived from herbal medicinal plants modulate various therapeutic targets and signaling pathways associated with cardiovascular diseases (CVDs), the world's primary cause of death. , a well-known traditional Chinese medicine with notable cardiovascular actions, has been used as a cardio- and cerebrovascular therapeutic drug and nutraceutical in Asian countries for centuries. Preclinical studies have shown that ginkgolide B, a bioactive component in , can ameliorate atherosclerosis in cultured vascular cells and disease models.
View Article and Find Full Text PDFEnhancing both oral bioavailability and anti-ischemic stroke efficacy of ginkgolide B by preparing nanocrystals self-stabilized Pickering nano-emulsion.
Eur J Pharm Sci
January 2024
Medical Mass Spectrometry Technology Innovation Center of Liaoning Province, Shenyang Harmony Health Medical Laboratory, Shenyang, Liaoning Province, China.
Ginkgolide B (GB), which has been demonstrated as the most efficacious naturally occurring platelet-activating factor (PAF) antagonist, is extensively utilized for the management of cardiovascular and cerebrovascular ailments. Nevertheless, its limited oral bioavailability is hindered by its low solubility in gastric acid and inadequate stability in intestinal fluid, thereby constraining its practical application. This study aimed to develop GB nanocrystals (GB-NCs) and GB nanocrystals self-stabilized Pickering nano-emulsion (GB-NSSPNE) using a miniaturized wet bead milling method.
View Article and Find Full Text PDFA sensitive LC-MS/MS method-based pharmacokinetic study of fifteen active ingredients of Yindan Xinnaotong soft capsule in rats and its potential mechanism in the treatment of cardiovascular diseases.
J Chromatogr B Analyt Technol Biomed Life Sci
April 2023
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing 210009, China. Electronic address:
Yindan Xinnaotong soft capsule (YDXNT) is a commonly used Chinese herbal preparation for the clinical treatment of coronary disease. However, there is a lack of pharmacokinetic studies on YDXNT, and its active ingredients and their mechanism in the treatment of cardiovascular diseases (CVD) are still unclear. In this study, 15 absorbed ingredients in rat plasma after oral administration of YDXNT were quickly identified based on liquid chromatography tandem quadrupole time-of-flight mass spectrometry (LC-QTOF MS), and then a sensitive and accurate quantitative method based on ultra-high performance liquid chromatography tandem triple quadrupole mass spectrometry (UHPLC-QQQ MS) was established and validated for simultaneous determination of the 15 ingredients of YDXNT in rat plasma, which was then applied to the pharmacokinetic study.
View Article and Find Full Text PDFPharmacokinetics of ginkgolide B-lyophilized nanoparticles after intravenous injection in rats using liquid chromatography-tandem mass spectrometry.
Rapid Commun Mass Spectrom
March 2023
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Rationale: Ginkgolide B (GB) performs diverse pharmacological activities but has poor water solubility. The currently available GB injections have a short half-life and are lethal when injected rapidly. We prepared GB-lyophilized nanoparticles (GB-NPs) using a new nonsurfactant polysaccharide polymer, ZY-010, as its carrier to regulate the release of GB in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!